Bloomsbury Genetic Therapies ("Bloomsbury") is a biotechnology company, developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies.
Launched in October 2022 with £5M in Seed funding from UCL Technology Fund, the Company is a spin-out of University College London and is underpinned by world-leading gene therapy and rare disease expertise from the Company’s academic founders, Professor Paul Gissen, Professor Manju Kurian, Professor Ahad Rahim and Professor Simon Waddington. Bloomsbury is building a pipeline of highly differentiated first- or best-in-class programs.
Launched in October 2022 with £5M in Seed funding from UCL Technology Fund, the Company is a spin-out of University College London and is underpinned by world-leading gene therapy and rare disease expertise from the Company’s academic founders, Professor Paul Gissen, Professor Manju Kurian, Professor Ahad Rahim and Professor Simon Waddington. Bloomsbury is building a pipeline of highly differentiated first- or best-in-class programs.
Location: United Kingdom, England, London
Employees: 1-10
Total raised: $5.6M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 28.10.2022 | UCL Techno... | ucltf.co.u... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.10.2022 | Seed | $5.6M | - |
Mentions in press and media 4
| Date | Title | Description |
| 01.02.2023 | Bloomsbury Genetic Therapies announces Orphan Drug Designations of BGT-DTDS for the treatment of Dopamine Transporter Deficiency Syndrome | |
| 06.10.2022 | Bloomsbury Genetic Therapies launches with Seed financing of £5 million to develop potentially curative gene therapy treatments for rare neurological and metabolic diseases | |
| 06.10.2022 | Bloomsbury Genetic Therapies launches with Seed financing of £5m to develop potentially curative gene therapy treatments for rare neurological and metabolic diseases | |
| - | Bloomsbury Genetic Therapies | “Bloomsbury Genetic Therapies – Dedicated to delivering the promise of gene therapy” |